Video

Dr. Janjigian on Pembrolizumab Triplet in HER2+ Esophagogastric Cancer

Yelena Y. Janjigian, MD, discusses the rationale behind the plasma and tumor-based biomarker analysis of pembrolizumab in combination with trastuzumab and chemotherapy in HER2-positive metastatic esophagogastric cancer.

Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale behind the plasma and tumor-based biomarker analysis of pembrolizumab (Keytruda) in combination with trastuzumab (Herceptin) and chemotherapy in HER2-positive metastatic esophagogastric cancer.

Patients on the trial experienced an unprecedented overall response rate (ORR) of 91%, according to Janjigian; this compared favorably with the historical control combination of chemotherapy and trastuzumab (Herceptin), as seen in the phase 3 ToGA study. In that study, chemotherapy plus trastuzumab demonstrated a 47% ORR in HER2-positive gastric cancer, says Janjigian.

Furthermore, the combination of pembrolizumab plus trastuzumab, capecitabine, and oxaliplatin resulted in durable progression-free survival, with 70% of patients progression free at 6 months, meeting the primary end point of the trial. The median overall survival in this population was 27 months, which was very impressive, according to Janjigian. Based on these data, the phase 3 KEYNOTE-811 study is accruing patients and the goal is to confirm the robust survival benefit seen with this approach.

Results from an analysis of tissue- and blood-based biomarkers conducted as part of the phase 2 study was presented at the 2020 ASCO Virtual Scientific Program. With this analysis, investigators were trying to determine how to predict which patients will respond and have durable responses to this treatment approach. Most patients will respond, says Janjigian; 100% of patients experienced a reduction in tumor burden. Since 16% of patients in this study experienced complete responses, it's important to determine which patients can potentially achieve cure with this combination in the long term, concludes Janjigian.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing [email protected], or by calling 833-315-2722.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity